IP Library Granted Patent US 8,846,872
Granted Patent B2
US 8,846,872 · App. 13/510,901 · Granted Sep 30, 2014

Monoclonal antibodies and diagnostic uses thereof

Inventors: Nathalie Kertesz (Agoura Hills, CA); Sutao Zhu (Alhambra, CA); Chih-Sheng Chiang (Chatsworth, CA)
Assignee: MannKind Corporation
G01N33/57484G01N33/5743C07K14/47C07K16/3053C07K2317/34
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,846,872
App. No.
13/510,901
Granted
Sep 30, 2014
Kind
B2
Abstract

The disclosure relates to antibodies to the preferentially expressed antigen in melanoma (PRAME), and the synovial sarcoma X breakpoint 2 (SSX-2) antigens, methods of use, and diagnostic kits thereof. In exemplary embodiments, the disclosure relates to monoclonal antibodies to specific epitopes of the PRAME and SSX-2 antigens and methods of using such antibodies.

Claims (17)

1. An antibody, or antigen-binding fragment thereof, directed against PRAME antigen that binds PRAME 123-132 (SEQ ID NO:1) or PRAME 276-286 (SEQ ID NO:2).

2. The antibody of claim 1 , wherein the antibody is a monoclonal antibody.

3. The antibody of claim 2 , wherein the antibody is a murine, chimeric, humanized, or human antibody.

4. The antibody of claim 3 , further linked to a label.

5. A method of detecting expression of tumor associated antigen PRAME in a biological sample, the method comprising

contacting the biological sample with an antibody of anyone of the preceding claims, and

detecting antibody bound to antigen in the sample, thereby detecting the expression of the tumor associated antigen.

6. The method of claim 5 , further comprising obtaining the biological sample from a subject.

7. The method of claim 5 , wherein the antibody is specific to SEQ ID NO:1.

8. The method of claim 5 , wherein the antibody is specific to SEQ ID NO:2.

9. The method of claim 6 , wherein the subject has cancer, and wherein the cancer is selected from the group consisting of melanoma, kidney, breast, pancreas, prostate, colorectal, liver, ovarian, non small cell lung cancer, glioblastoma, ocular melanoma, hormone sensitive and hormone refractory prostate cancer, renal cell carcinoma, esophageal, endometrial cancer, uterine cancer, lymphoma, soft tissue sarcoma, multiple myeloma, gallbladder cancer, thyroid and mesothelioma.

10. The method of claim 5 , wherein the biological sample comprises a biopsy specimen, a tissue, a cell, blood, ascites, pleural fluid, or a soluble protein.

11. The method of claim 5 , wherein expression of PRAME is detected by immunofluorescence microscopy, immunocytochemistry, immunohistochemistry, ELISA, FACS analysis or immunoprecipitation.

12. A plasmid operably encoding the antibody, or an antigen binding fragment thereof, of claim 1 .

13. A hybridoma that produces a monoclonal antibody of claim 2 .

14. A kit comprising the antibody, or antigen binding fragment thereof, of claim 1 .

15. The antibody, or antigen-binding fragment thereof, of claim 1 , wherein the antibody, or antigen-binding fragment thereof, also binds a fragment of PRAME.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2012
From: KERTESZ, NATHALIE; ZHU, SUTAO; CHIANG, CHIH-SHENG
To: MANNKIND CORPORATION
Reel/Frame 029210/0411 →
Continuity (2)
Provisional Application 61262538 · Nov 18, 2009
Related Publication 20130029359A1 · Jan 31, 2013